Cellectis (CLLS) Receivables Refunds (2022 - 2026)

Name: Cellectis (CLLS) Receivables Refunds (2022 - 2026) | Business Quant
Creator: Business Quant

Cellectis (CLLS) posted Receivables Refunds of -$46000.0 for Q1 2026, up 91.05% on a QoQ basis from -$514000.0 in Q4 2025.

Cellectis (CLLS) has 5 years of Receivables Refunds data on file, last reported at -$46000.0 in Q1 2026.

In Q1 2026, Receivables Refunds changed N/A year-over-year to -$46000.0; the TTM figure through Mar 2026 stood at -$46000.0 (changed N/A YoY), while the FY2025 annual figure was -$514000.0, changed N/A from the prior year.
Receivables Refunds climbed to -$46000.0 in Q1 2026, from -$514000.0 in the prior quarter.
Across five years, Receivables Refunds topped out at $455000.0 in Q2 2024 and bottomed at -$514000.0 in Q3 2024.
A 5-year average of -$43125.0 and a median of -$66500.0 in 2022 frame the typical range for Receivables Refunds.
The widest YoY moves for Receivables Refunds: up 76.36% in 2024, down 240.82% in 2024.
Year by year, Receivables Refunds stood at -$87000.0 in 2022, then soared by 519.54% to $365000.0 in 2023, then sank by 240.82% to -$514000.0 in 2024, then changed by 0.0% to -$514000.0 in 2025, then surged by 91.05% to -$46000.0 in 2026.
The last three Receivables Refunds figures came in at -$46000.0 (Q1 2026), -$514000.0 (Q4 2025), and -$514000.0 (Q3 2024), per Business Quant data.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Refund Receivables (Qtr)
1	Quantum Biopharma	1,216,509.61 Bn	1,216,509.61 Bn	-	-
2	Alterity Therapeutics	764,224.41 Bn	764,224.38 Bn	-	-
3	Legend Biotech	2,716.00 Bn	2,715.71 Bn	242.10 Mn	-
4	Nanobiotix	2,248.83 Bn	2,248.77 Bn	-	-
5	Akari Therapeutics	1,951.18 Bn	1,951.17 Bn	-	-
6	Vertex Pharmaceuticals	113.69 Bn	106.44 Bn	2.59 Bn	-
7	Evaxion A	64.16 Bn	64.14 Bn	-	-
8	Regeneron Pharmaceuticals	63.94 Bn	55.18 Bn	3.31 Bn	-
9	Alnylam Pharmaceuticals	40.13 Bn	37.12 Bn	959.66 Mn	-
10	Cellectis	20.83 Bn	20.62 Bn	-	-46,000.00

Download Data 🔒